Mai Othman, Eman Khedr, Shimaa Heikal, Mohamed H Yousef, Gharib Fawi, Sara El Farrash, Samer Salama, Muhammad Abdelshafi, Nesma G Elsheikh, Heba M Tawfik, Hany I Hassanin, Nourelhoda A Haridy, Gellan K Ahmed, Noha Abo Elftoh, Amna Ibrahim, Ahmed Qayaty, Eman M Ali, Agsha Atputhavadivel, Samir Shamma, Noha A Yousri, Mie Rizig, Mohamed Salama
{"title":"<i>APOE</i>-associated disease risk and sex-specific effects in Egyptian Alzheimer's disease: an exploratory study.","authors":"Mai Othman, Eman Khedr, Shimaa Heikal, Mohamed H Yousef, Gharib Fawi, Sara El Farrash, Samer Salama, Muhammad Abdelshafi, Nesma G Elsheikh, Heba M Tawfik, Hany I Hassanin, Nourelhoda A Haridy, Gellan K Ahmed, Noha Abo Elftoh, Amna Ibrahim, Ahmed Qayaty, Eman M Ali, Agsha Atputhavadivel, Samir Shamma, Noha A Yousri, Mie Rizig, Mohamed Salama","doi":"10.1002/trc2.70268","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The apolipoprotein E (<i>APOE</i>) gene is the strongest known genetic risk factor for late-onset Alzheimer's disease (AD), particularly the ε4 allele. Evidence suggests that women carrying at least one <i>APOE</i> ε4 allele have a higher risk of developing AD compared to men. However, data addressing genetic risk and sex-specific effects in Middle Eastern and North African populations remain limited.</p><p><strong>Methods: </strong>To address this gap, we evaluated <i>APOE</i> allele frequencies, their association with AD risk, and their contribution to sex-specific variability in a cohort of 63 clinically diagnosed AD patients and 201 cognitively healthy controls recruited across Egypt.</p><p><strong>Results: </strong>The <i>APOE</i> ε3 allele was the most prevalent in both AD cases (83.3%) and controls (83.6%). The ε4 allele was more frequent among AD patients (12.7%) than controls (8.0%) (adjusted odds ratio [OR] = 1.09, 95% confidence interval [CI]: 0.46 to 2.49, <i>p</i> = 0.85), while the ε2 allele was less frequent in AD patients (4.0%) compared to controls (8.5%) (adjusted OR = 0.82, 95% CI: 0.24 to 2.36, <i>p</i> = 0.73). However, neither association reached statistical significance after Benjamini-Hochberg false discovery rate correction. Sex-stratified analyses revealed no significant sex-specific effects of <i>APOE</i> alleles.</p><p><strong>Conclusion: </strong>This pilot study provides the first characterization of <i>APOE</i> genotype and allele frequencies in Egyptians with clinically confirmed AD. No statistically significant association was observed between <i>APOE</i> status and AD risk in either males or females. Larger, geographically representative studies are needed to further elucidate the role of <i>APOE</i> in AD susceptibility within the Egyptian population and to explore potential alternative genetic or environmental contributors.</p>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"12 2","pages":"e70268"},"PeriodicalIF":7.4000,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13240464/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/trc2.70268","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The apolipoprotein E (APOE) gene is the strongest known genetic risk factor for late-onset Alzheimer's disease (AD), particularly the ε4 allele. Evidence suggests that women carrying at least one APOE ε4 allele have a higher risk of developing AD compared to men. However, data addressing genetic risk and sex-specific effects in Middle Eastern and North African populations remain limited.
Methods: To address this gap, we evaluated APOE allele frequencies, their association with AD risk, and their contribution to sex-specific variability in a cohort of 63 clinically diagnosed AD patients and 201 cognitively healthy controls recruited across Egypt.
Results: The APOE ε3 allele was the most prevalent in both AD cases (83.3%) and controls (83.6%). The ε4 allele was more frequent among AD patients (12.7%) than controls (8.0%) (adjusted odds ratio [OR] = 1.09, 95% confidence interval [CI]: 0.46 to 2.49, p = 0.85), while the ε2 allele was less frequent in AD patients (4.0%) compared to controls (8.5%) (adjusted OR = 0.82, 95% CI: 0.24 to 2.36, p = 0.73). However, neither association reached statistical significance after Benjamini-Hochberg false discovery rate correction. Sex-stratified analyses revealed no significant sex-specific effects of APOE alleles.
Conclusion: This pilot study provides the first characterization of APOE genotype and allele frequencies in Egyptians with clinically confirmed AD. No statistically significant association was observed between APOE status and AD risk in either males or females. Larger, geographically representative studies are needed to further elucidate the role of APOE in AD susceptibility within the Egyptian population and to explore potential alternative genetic or environmental contributors.
期刊介绍:
Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.